RIVIVE Drug Patent Profile
✉ Email this page to a colleague
When do Rivive patents expire, and when can generic versions of Rivive launch?
Rivive is a drug marketed by Harm Reduction Therp and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-six countries.
The generic ingredient in RIVIVE is naloxone hydrochloride. There are twelve drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rivive
A generic version of RIVIVE was approved as naloxone hydrochloride by HOSPIRA on September 24th, 1986.
Summary for RIVIVE
| International Patents: | 51 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in RIVIVE? | RIVIVE excipients list |
| DailyMed Link: | RIVIVE at DailyMed |
Pharmacology for RIVIVE
| Drug Class | Opioid Antagonist |
| Mechanism of Action | Opioid Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for RIVIVE
US Patents and Regulatory Information for RIVIVE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harm Reduction Therp | RIVIVE | naloxone hydrochloride | SPRAY, METERED;NASAL | 217722-001 | Jul 28, 2023 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Harm Reduction Therp | RIVIVE | naloxone hydrochloride | SPRAY, METERED;NASAL | 217722-001 | Jul 28, 2023 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RIVIVE
See the table below for patents covering RIVIVE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Mexico | 2013013276 | FORMAS DE DOSIFICACION FARMACEUTICAS INTRANASALES QUE COMPRENDEN NALOXONA. (INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE.) | ⤷ Sign Up |
| South Africa | 201308280 | Intranasal pharmaceutical dosage forms comprising naloxone | ⤷ Sign Up |
| Russian Federation | 2013155479 | ИНТРАНАЗАЛЬНЫЕ ФАРМАЦЕВТИЧЕСКИЕ ДОЗИРОВАННЫЕ ФОРМЫ, СОДЕРЖАЩИЕ НАЛОКСОН | ⤷ Sign Up |
| Cyprus | 1120399 | ⤷ Sign Up | |
| Australia | 2016204880 | Intranasal pharmaceutical dosage forms comprising naloxone | ⤷ Sign Up |
| Philippines | 12016501342 | INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE | ⤷ Sign Up |
| Japan | 2014513683 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RIVIVE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | 92292 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
